ARS 7: The Convergence of Pharma and Medtech

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Grant Support/Research Contract - Abbott, Affluent Medical, Alleviant Medical, Amgen, AstraZeneca, BAIM, Beth Israel Deaconess Medical Center, Boston Scientific, Bristol-Myers Squibb, CardiaWave, CERC, Chiesi, Concept Medical, Daiichi Sankyo, Duke, Faraday, Idorsia, Janssen, MedAlliance, ; Abbott, Alleviant Medical, Chiesi, Concept Medical, Cordis, CPC Clinical Research, Daiichi Sankyo, Duke, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, Medtronic, NewAmsterdam Pharma, Novartis, Novo Nordisk Inc., Population Health</li><li>Equity/Stock(s)/Options - Elixir Medical, Stel, ControlRad (spouse)</li><li>No Fees - SCAI (Women in Innovations Committee Member), Faculty Cardiovascular Research Foundation (CRF), Women as One</li><li>Consultant Fee/Honoraria/Speaker's Bureau - AMA - JAMA Cardiology (Associate Editor), ACC (BOT Member, SC Member CTR Program)</li></ul>